CONTACT: COMPANY CONTACT: Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications Raptor Pharmaceutical Corp. (415) 408-6351 INVESTOR CONTACT: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 firstname.lastname@example.org MEDIA CONTACT: Cammy Duong Canale Communications (619) 849-5382 email@example.com
NOVATO, Calif., Aug. 20, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 10 th Annual North Bay Business Journal competition. The results of the best places to work in the North Bay, will be featured in the September 28, 2015 publication of the North Bay Business Journal. "We are incredibly proud that our employees have placed Raptor among the best places to work in the North Bay," stated Julie Anne Smith, President and CEO of Raptor. "This recognition speaks volumes about our unique culture, dedication to excellence and personal commitment to patients. This is an exciting place to work and I am very honored that our employees feel the same way." About the Best Places to Work Survey The North Bay Business Journal's editorial staff selected the winning companies from over 150 applications using results of a company questionnaire, an employee engagement survey and other selection criteria. About Raptor Pharmaceutical Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), pediatric nonalcoholic steatohepatitis (NASH), and mitochondrial diseases including Leigh's syndrome. Raptor holds several orphan drug designations, including orphan drug exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.